To evaluate if the rescue of MHC I expression triggered by NLRC5 overexpression could influence tumor development through the MHC-I-peptide-CTL axis, in vivo tumor growth was assessed in different TMEs, by subcutaneous (SC), orthotopic (under the ovarian bursa, IB), or intraperitoneal (IP) injections of ID8-p53−/− and ID8-p53−/−NLRC5+ cells into C57BL/6 mice. This evidence concerns the gene TP53 and neoplasm.